Search Results for "Immunotherapy"

Watch this video on balancing immune-related adverse events (irAEs) treatment with infection risk. 

Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.

Gastrointestinal side effects with immunotherapy can manifest as diarrhea, abdominal pain, or melena.

As the use of CAR T-Cell therapy grows, understanding the events involved, the adverse events associated with this therapy and evidence-based management strategies is critical. Use this resource to enhance your understanding of the process behind CAR T-Cell therapy and nursing considerations associated with the treatment. 

Watch this ONS video on adoptive T-cell transfer for B-cell malignancies. 

Learn more about best practices for personal protective equipment during administration, compounding, and spill management of checkpoint inhibitors.